Drugs / BRC-OA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06828666 | May 2025 → Feb 2026 overdue | osteoarthritis, knee | Britecyte | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-01 | Britecyte | Regulatory Britecyte’s adipose tissue allograft earns FDA “Safe to Proceed” status britecyte.com ↗
Amarex announced that work on behalf of Britecyte resulted in a “safe to proceed” status from the U.S. Food and Drug Administration (FDA) for Britecyte’s Adipose Tissue Allograft (BRC-OA). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-01 | Britecyte | MSCRF awards $1M clinical grant for BRC-OA knee osteoarthritis study britecyte.com ↗ |
| 2025-02-01 | Britecyte | Britecyte’s adipose tissue allograft earns FDA “Safe to Proceed” status britecyte.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRC-OA | “BRC-OA is a Cryopreserved Devitalized Adipose Tissue Allograft that has demonstrated anti-inflammatory and antioxidant properties of adipose tissue.” NCT06828666 ↗ |
| Modality | Other / unclassified | “Cryopreserved Devitalized Adipose Tissue Allograft” NCT06828666 ↗ |
| Route | Other | “via intra-articular injection” NCT06828666 ↗ |